Glucagon is used as an emergency medical treatment when the level of blood sugar goes down drastically. Patients suffering from diabetes are the major user of this therapy.

Market Dynamics

Gradual increase in number of patients suffering from hypoglycaemia across the globe, rapid advancement in healthcare sector and manufacturers approach towards introduction of innovative solutions are major factors expected to drive the growth of the global glucagon therapy market. Changing lifestyle pattern and increasing consumption of unhealthy food is resulting in various health issues. According to Centers for Disease Control and Prevention in 2015, an estimated 1.5 million new cases of diabetes were diagnosed among people aged 18 and older. About 210,000 Americans under age 20 are estimated to have diagnosed diabetes, approximately 0.25% of that population. Governments of developed and developing countries are spending high on development of healthcare sector to strengthen the R&D capabilities and facilitate the medical service is gaining traction. Consumers demand for minimally invasive medication is increasing their approach towards consumption of powder medication. High investment by drug manufacturers for new drug development, increasing clinical trials and approvals from the government bodies are factors responsible to support the revenue growth of glucagon therapy market. In 2019, the FDA approved the first Baqsimi nasal powder for glucagon therapy as the emergency treatment of severe hypoglycemia that can be administered without an injection.

Increasing R&D activities by major players for product development and inclination towards introduction of new products in order to attract new customers are factors expected to augment the growth of glucagon therapy market.

In 2020, Fresenius Kabi launched glucagon emergency medicine kit to treat life-threatening episodes of low blood sugar. This product launch is expected to help the company to enhance the business presence and increase the product portfolio.

In 2019, Eli Lilly and Company launched Baqsimi for glucagon in the US market. This is expected to help the company to enhance the customer base in US and increase the revenue share.

Manufactures approach towards tracking the untapped market in emerging economies and enhance the business presence through strategic partnership are expected to impact the growth of glucagon therapy market. Factors such as stringent government regulations related to product approval and high cost associated to R&D activities are expected to hamper the growth of global glucagon therapy market. In addition, lack of awareness among consumers related to therapy is expected to challenge the growth of glucagon therapy market. However, increasing investment by major players for R&D activities and introduction of innovative solutions are factors expected to create new opportunities for players operating in the glucagon therapy market. In addition, increasing partnership and agreements in order to strengthen the product distribution is expected to support the revenue transaction of the target market.

Segment Analysis by Region

The market in North America is expected to account for major revenue share in the global glucagon therapy market due to high patient pool suffering from diabetes. In addition, favorable reimbursement policies and availability of developed R&D facilities for introduction of innovative solution are factors expected to support the growth of target market.

Presence of large number of players operating in the country and approach towards enhancing the customer base and increase the revenue share through acquisitions are factors expected to boost the glucagon therapy regional market growth.

The market in Asia Pacific is expected to witness faster growth in the glucagon therapy market due high spending capacity and rising concern related to health among consumers. In addition, rising manufacturers focus on enhancing the business presence through strategic agreement is expected to support the growth of glucagon therapy regional market.

Competitive Landscape      

The global glucagon therapy market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Report coverage

Market	Global Glucagon Therapy Market
Analysis Period	2016 – 2027
Base Year	2019
Forecast Data	2020 – 2027
Market Stratification	Product Type, Application, End Use and Geography
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Report Coverage	Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis

Glucagon Therapy Market Segment Analysis, 2019

The global glucagon therapy market is segmented into product type, application, and end use. The product type segment is bifurcated into injectable glucagon and nasal glucagon. Among product type the nasal glucagon segment is expected to account for major revenue share in the target market. The application segment is divided into general use, emergency kit, diagnostic and motility, cardiogenic shock, and others. Among the application, the diagnostic and motility segment is expected to account for significant revenue share in the target segment. The players profiled in the report are Xeris Pharmaceuticals Inc., Svar Life Science AB, Novo Nordisk A/S, Eli Lilly and Co., Taj Pharmaceuticals Ltd., Fresenius SE and Co. KGaA and Torrent Pharmaceuticals Ltd.

Market Segmentation

Market By Product Type

Injectable Glucagon

Nasal Glucagon

Market By Application

General Use

Emergency kit

Diagnostic and Motility

Cardiogenic Shock

Others

Market By End Use

Hospitals

Specialty Clinics

Market By Region

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa

TABLE OF CONTENT